The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Very low price/earnings valuation as compared to others within industry, of close to ~ 9. Market cap of 38.22 billion leaves a bit of room to grow, but also shows established presence. Concern over drug pipeline is dwarfed by potential to find and cultivate new drugs, particularly in niche markets such as Alzheimer's. Took a look at valuation statistics and numbers including return on assets, return on equity, profit margin, operating margin, and debt/equity all look promising.